查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1266323

白血病治疗市场：按类型、药物类别和分销渠道分类：2021-2031 年全球机会分析和行业预测

Leukemia Therapeutics Market By Type, By Drug Class, By Distribution channel : Global Opportunity Analysis and Industry Forecast, 2021-2031
出版日期: | 出版商: Allied Market Research | 英文 392 Pages | 商品交期: 2-3个工作天内

价格

2021 年全球白血病治疗市场价值 781863 万美元，预计 2031 年将达到 141亿6248 万美元，2022 年至 2031 年的复合年增长率为 6.1%。

白血病是一种影响血液和骨髓的血癌。 它的特点是异常白细胞不受控制地产生，会干扰血液和免疫系统的正常功能。 白血病的类型包括急性淋巴细胞白血病 (ALL)、急性髓性白血病 (AML)、慢性淋巴细胞白血病 (CLL) 和慢性粒细胞白血病 (CML)。 罕见类型的白血病包括慢性粒单核细胞白血病 (CMML) 和幼年粒单核细胞白血病 (JMML)。 根据白血病的类型和阶段以及患者的健康状况，这些罕见类型的白血病的治疗可能与化疗等相结合。 白血病的症状包括疲劳、虚弱、频繁感染以及容易瘀伤和出血。

许多非处方药已被开髮用于治疗白血病，推动了对白血病治疗的需求。 一些最常用的药物包括 Gleevec、Bosulif、Sprycel 和 Iculsig。 这些药物在治疗白血病方面显示出了巨大的疗效，并已成为许多患者的标准治疗。 此外，用于治疗白血病的新型和改进药物的开发正在推动对白血病治疗的需求。

由于全球白血病患者数量的增加和骨髓活检数量的增加，白血病治疗市场正在增长。 此外，白血病研发活动投入的增加以及人们对靶向治疗意识的增强进一步推动了白血病治疗市场的增长。 新药的推出提高了白血病患者的生存率，增加了他们战胜白血病的机会，进一步推动了市场增长。

另一方面，白血病治疗的监管审批很紧，白血病治疗药物的副作用阻碍了市场增长。 例如，Onureg（阿扎胞甘）会导致白血病患者头晕、噁心、呕吐、疲劳、贫血和血小板计数低。 此外，用于治疗白血病的药物专利到期和高昂的治疗费用也限制了全球白血病治疗市场的增长。 此外，越来越多的白血病临床试验和新产品批准有望不仅在新兴市场，而且在发达市场创造新的机会。 例如，2020年12月，安进宣布美国食品药品监督管理局（FDA）批准利妥昔单抗（rituximab）的生物仿製药RIABNI（rituximab-arrx）用于治疗成年慢性淋巴细胞白血病（CLL）患者。

内容

第 1 章介绍

第 2 章执行摘要

第 3 章市场概述

  • 市场定义和范围
  • 主要发现
    • 顶级影响因子
    • 顶级投资基金
  • 波特的五力分析
    • 供应商的议价能力
    • 买家的议价能力
    • 替代品的威胁
    • 新进入者的威胁
    • 竞争对手的实力
  • 市场动态
    • 促进因素
      • 白血病发病率增加
      • 提高产品批准率
    • 抑制因素
      • 白血病治疗的副作用和副作用
      • 白血病治疗费用高昂
    • 机会
      • 新兴经济体的高增长潜力
      • 增加研发活动
  • 分析 COVID-19 对市场的影响

第 4 章白血病治疗市场：按类型

  • 概览
    • 市场规模和预测
  • 急性淋巴细胞白血病
    • 主要市场趋势、增长动力和机遇
    • 市场规模和预测：按地区
    • 市场份额分析：国家/地区分析
  • 急性髓性白血病
    • 主要市场趋势、增长动力和机遇
    • 市场规模和预测：按地区
    • 市场份额分析：国家/地区分析
  • 慢性淋巴细胞白血病
    • 主要市场趋势、增长动力和机遇
    • 市场规模和预测：按地区
    • 市场份额分析：国家/地区分析
  • 慢性粒细胞白血病
    • 主要市场趋势、增长动力和机遇
    • 市场规模和预测：按地区
    • 市场份额分析：国家/地区分析
  • 其他
    • 主要市场趋势、增长动力和机遇
    • 市场规模和预测：按地区
    • 市场份额分析：国家/地区分析

第 5 章白血病治疗市场：按药物类别分类

  • 概览
    • 市场规模和预测
  • 化疗
    • 主要市场趋势、增长动力和机遇
    • 市场规模和预测：按地区
    • 市场份额分析：国家/地区分析
  • 靶向治疗和免疫治疗
    • 主要市场趋势、增长动力和机遇
    • 市场规模和预测：按地区
    • 市场份额分析：国家/地区分析

第 6 章白血病治疗市场：按分销渠道

  • 概览
    • 市场规模和预测
  • 医院药房
    • 主要市场趋势、增长动力和机遇
    • 市场规模和预测：按地区
    • 市场份额分析：国家/地区分析
  • 药店和商店式配药店
    • 主要市场趋势、增长动力和机遇
    • 市场规模和预测：按地区
    • 市场份额分析：国家/地区分析
  • 在线提供商
    • 主要市场趋势、增长动力和机遇
    • 市场规模和预测：按地区
    • 市场份额分析：国家/地区分析

第 7 章白血病治疗市场：按地区

  • 概览
    • 市场规模和预测：按地区
  • 北美
    • 主要趋势和机会
    • 市场规模/预测：按类型
    • 市场规模和预测：按药物类别
    • 市场规模和预测：按分销渠道
    • 市场规模/预测：按国家/地区分类
      • 美国
      • 主要市场趋势、增长动力和机遇
      • 市场规模/预测：按类型
      • 市场规模和预测：按药物类别
      • 市场规模和预测：按分销渠道
      • 加拿大
      • 主要市场趋势、增长动力和机遇
      • 市场规模/预测：按类型
      • 市场规模和预测：按药物类别
      • 市场规模和预测：按分销渠道
      • 墨西哥
      • 主要市场趋势、增长动力和机遇
      • 市场规模/预测：按类型
      • 市场规模和预测：按药物类别
      • 市场规模和预测：按分销渠道
  • 欧洲
    • 主要趋势和机会
    • 市场规模/预测：按类型
    • 市场规模和预测：按药物类别
    • 市场规模和预测：按分销渠道
    • 市场规模/预测：按国家/地区分类
      • 德国
      • 主要市场趋势、增长动力和机遇
      • 市场规模/预测：按类型
      • 市场规模和预测：按药物类别
      • 市场规模和预测：按分销渠道
      • 法国
      • 主要市场趋势、增长动力和机遇
      • 市场规模/预测：按类型
      • 市场规模和预测：按药物类别
      • 市场规模和预测：按分销渠道
      • 英国
      • 主要市场趋势、增长动力和机遇
      • 市场规模/预测：按类型
      • 市场规模和预测：按药物类别
      • 市场规模和预测：按分销渠道
      • 意大利
      • 主要市场趋势、增长动力和机遇
      • 市场规模/预测：按类型
      • 市场规模和预测：按药物类别
      • 市场规模和预测：按分销渠道
      • 西班牙
      • 主要市场趋势、增长动力和机遇
      • 市场规模/预测：按类型
      • 市场规模和预测：按药物类别
      • 市场规模和预测：按分销渠道
      • 其他欧洲
      • 主要市场趋势、增长动力和机遇
      • 市场规模/预测：按类型
      • 市场规模和预测：按药物类别
      • 市场规模和预测：按分销渠道
  • 亚太地区
    • 主要趋势和机会
    • 市场规模/预测：按类型
    • 市场规模和预测：按药物类别
    • 市场规模和预测：按分销渠道
    • 市场规模/预测：按国家/地区分类
      • 日本
      • 主要市场趋势、增长动力和机遇
      • 市场规模/预测：按类型
      • 市场规模和预测：按药物类别
      • 市场规模和预测：按分销渠道
      • 中国
      • 主要市场趋势、增长动力和机遇
      • 市场规模/预测：按类型
      • 市场规模和预测：按药物类别
      • 市场规模和预测：按分销渠道
      • 印度
      • 主要市场趋势、增长动力和机遇
      • 市场规模/预测：按类型
      • 市场规模和预测：按药物类别
      • 市场规模和预测：按分销渠道
      • 澳大利亚
      • 主要市场趋势、增长动力和机遇
      • 市场规模/预测：按类型
      • 市场规模和预测：按药物类别
      • 市场规模和预测：按分销渠道
      • 韩国
      • 主要市场趋势、增长动力和机遇
      • 市场规模/预测：按类型
      • 市场规模和预测：按药物类别
      • 市场规模和预测：按分销渠道
      • 其他亚太地区
      • 主要市场趋势、增长动力和机遇
      • 市场规模/预测：按类型
      • 市场规模和预测：按药物类别
      • 市场规模和预测：按分销渠道
  • 拉美
    • 主要趋势和机会
    • 市场规模/预测：按类型
    • 市场规模和预测：按药物类别
    • 市场规模和预测：按分销渠道
    • 市场规模/预测：按国家/地区分类
      • 巴西
      • 主要市场趋势、增长动力和机遇
      • 市场规模/预测：按类型
      • 市场规模和预测：按药物类别
      • 市场规模和预测：按分销渠道
      • 沙特阿拉伯
      • 主要市场趋势、增长动力和机遇
      • 市场规模/预测：按类型
      • 市场规模和预测：按药物类别
      • 市场规模和预测：按分销渠道
      • 南非
      • 主要市场趋势、增长动力和机遇
      • 市场规模/预测：按类型
      • 市场规模和预测：按药物类别
      • 市场规模和预测：按分销渠道
      • LAMEA 的其余部分
      • 主要市场趋势、增长动力和机遇
      • 市场规模/预测：按类型
      • 市场规模和预测：按药物类别
      • 市场规模和预测：按分销渠道

第 8 章竞争格局

  • 介绍
  • 关键成功策略
  • 10 家主要公司的产品映射
  • 比赛仪表板
  • 竞争热图
  • 定位顶级公司，2021 年

第 9 章公司简介

  • Abbvie Inc
  • Amgen Inc.
  • Pfizer Inc.
  • Novartis AG
  • Gilead Sciences, Inc.
  • Bristol-Myers Squibb Company
  • Sanofi
  • Teva Pharmaceutical Industries Limited
  • Lupin
  • Takeda Pharmaceutical Company Limited
Product Code: A01128

The global leukemia therapeutics market valued for $7,818.63 million in 2021 and is estimated to reach $14,162.48 million by 2031, exhibiting a CAGR of 6.1% from 2022 to 2031.  

Leukemia is a type of blood cancer that affects the blood and bone marrow. It is characterized by the uncontrolled production of abnormal white blood cells, which can interfere with the normal functioning of the blood and the immune system. There are several types of leukemia, including acute lymphocytic leukemia (ALL), acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL), and chronic myeloid leukemia (CML). The rare types of leukemia include chronic myelomonocytic leukemia (CMML), and juvenile myelomonocytic leukemia (JMML). Treatment for these rare forms of leukemia may involve a combination of chemotherapy, and others treatment depending on the type and stage of the leukemia and the overall health of the patient. Symptoms of leukemia can include fatigue, weakness, frequent infections, and easy bruising or bleeding.

A number of commercially available drugs have been developed to treat leukemia and are driving the demand for leukemia therapeutics. Some of the most commonly used drugs include Gleevec, Bosulif, Sprycel, Iculsig, and others. These drugs have shown significant efficacy in the treatment of leukemia and have become the standard of care for many patients. In addition, the development of new and improved drugs for the treatment of leukemia drives the demand for leukemia therapeutics.

The leukemia therapeutics market is experiencing growth owing to rise in cases of leukemia and the number of bone marrow biopsies across the world. In addition, the increase in investment in the R&D activities for leukemia and rise in awareness of the targeted therapies among the population further drive the growth of the leukemia therapeutics market. The introduction of new drugs has led to improved survival rates for patients with leukemia, giving them a better chance of beating the disease which further supports the market growth.

In contrast, the stringent regulatory approvals for the leukemia therapeutics and the side effect of the drugs used in the leukemia treatment impedes the growth of the market. For instance, Onureg (azacitidine) causes dizziness, nausea, vomiting, fatigue, anemia, and low platelet count in patients with leukemia. In addition, patent expiry of the drugs used in the treatment of leukemia and the higher costs involved in the therapies limit the growth of the global leukemia therapeutics market. Moreover, the rise in number of clinical trials for leukemia and new product approvals are anticipated to create newer opportunities in the emerging as well as the developed markets. For instance, in December 2020, Amgen announced the U.S. Food and Drug Administration (FDA) has approved RIABNI (rituximab-arrx), a biosimilar to Rituxan (rituximab), for the treatment of adult patients with chronic lymphocytic leukemia (CLL).

The global leukemia therapeutics market is segmented into type, drug class, distribution channel, and region. By type, the market is categorized into acute lymphocytic leukemia, acute myeloid leukemia, chronic lymphocytic leukemia, chronic myeloid leukemia, and others. On the basis of drug class, the market is segregated into chemotherapy, and targeted & immunotherapy. By distribution channel, the market is classified into hospital pharmacies, drug stores & retail pharmacies, and online providers. Region wise, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).  

Major key players that operate in the global leukemia therapeutics market are: AbbVie Inc. Amgen Inc., Bristol-Myers Squibb Company, Gilead Sciences, Inc., Lupin, Novartis AG, Pfizer Inc., Sanofi, Takeda Pharmaceutical Company Limited, and Teva Pharmaceutical Industries Limited. 

Key Benefits For Stakeholders

  • This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the global leukemia therapeutics market analysis from 2021 to 2031 to identify the prevailing global leukemia therapeutics market opportunities.
  • The market research is offered along with information related to key drivers, restraints, and opportunities.
  • Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
  • In-depth analysis of the global leukemia therapeutics market segmentation assists to determine the prevailing market opportunities.
  • Major countries in each region are mapped according to their revenue contribution to the global market.
  • Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
  • The report includes the analysis of the regional as well as global leukemia therapeutics market trends, key players, market segments, application areas, and market growth strategies.

Key Market Segments

By Type

  • Acute Lymphocytic Leukemia
  • Acute Myeloid Leukemia
  • Chronic Lymphocytic Leukemia
  • Chronic Myeloid Leukemia
  • Others

By Drug Class

  • Chemotherapy
  • Targeted Therapy and Immunotherapy

By Distribution channel

  • Hospital Pharmacies
  • Drug Store and Retail Pharmacies
  • Online Providers

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • UK
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • Japan
    • China
    • India
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • LAMEA
    • Brazil
    • Saudi Arabia
    • South Africa
    • Rest of LAMEA

Key Market Players

  • Amgen Inc.
  • Bristol-Myers Squibb Company
  • Lupin
  • Sanofi
  • Gilead Sciences, Inc.
  • Takeda Pharmaceutical Company Limited
  • Abbvie Inc
  • Pfizer Inc.
  • Teva Pharmaceutical Industries Limited
  • Novartis AG

TABLE OF CONTENTS

CHAPTER 1: INTRODUCTION

  • 1.1. Report description
  • 1.2. Key market segments
  • 1.3. Key benefits to the stakeholders
  • 1.4. Research Methodology
    • 1.4.1. Primary research
    • 1.4.2. Secondary research
    • 1.4.3. Analyst tools and models

CHAPTER 2: EXECUTIVE SUMMARY

  • 2.1. CXO Perspective

CHAPTER 3: MARKET OVERVIEW

  • 3.1. Market definition and scope
  • 3.2. Key findings
    • 3.2.1. Top impacting factors
    • 3.2.2. Top investment pockets
  • 3.3. Porter's five forces analysis
    • 3.3.1. Bargaining power of suppliers
    • 3.3.2. Bargaining power of buyers
    • 3.3.3. Threat of substitutes
    • 3.3.4. Threat of new entrants
    • 3.3.5. Intensity of rivalry
  • 3.4. Market dynamics
    • 3.4.1. Drivers
      • 3.4.1.1. Rise in incidences of leukemia
      • 3.4.1.2. Rise in product approval
    • 3.4.2. Restraints
      • 3.4.2.1. Side-effects and adverse reactions of leukemia therapeutics
      • 3.4.2.2. High cost of leukemia therapeutics
    • 3.4.3. Opportunities
      • 3.4.3.1. High growth potential in developing economies
      • 3.4.3.2. Increase in R&D activities
  • 3.5. COVID-19 Impact Analysis on the market

CHAPTER 4: LEUKEMIA THERAPEUTICS MARKET, BY TYPE

  • 4.1. Overview
    • 4.1.1. Market size and forecast
  • 4.2. Acute Lymphocytic Leukemia
    • 4.2.1. Key market trends, growth factors and opportunities
    • 4.2.2. Market size and forecast, by region
    • 4.2.3. Market share analysis by country
  • 4.3. Acute Myeloid Leukemia
    • 4.3.1. Key market trends, growth factors and opportunities
    • 4.3.2. Market size and forecast, by region
    • 4.3.3. Market share analysis by country
  • 4.4. Chronic Lymphocytic Leukemia
    • 4.4.1. Key market trends, growth factors and opportunities
    • 4.4.2. Market size and forecast, by region
    • 4.4.3. Market share analysis by country
  • 4.5. Chronic Myeloid Leukemia
    • 4.5.1. Key market trends, growth factors and opportunities
    • 4.5.2. Market size and forecast, by region
    • 4.5.3. Market share analysis by country
  • 4.6. Others
    • 4.6.1. Key market trends, growth factors and opportunities
    • 4.6.2. Market size and forecast, by region
    • 4.6.3. Market share analysis by country

CHAPTER 5: LEUKEMIA THERAPEUTICS MARKET, BY DRUG CLASS

  • 5.1. Overview
    • 5.1.1. Market size and forecast
  • 5.2. Chemotherapy
    • 5.2.1. Key market trends, growth factors and opportunities
    • 5.2.2. Market size and forecast, by region
    • 5.2.3. Market share analysis by country
  • 5.3. Targeted Therapy and Immunotherapy
    • 5.3.1. Key market trends, growth factors and opportunities
    • 5.3.2. Market size and forecast, by region
    • 5.3.3. Market share analysis by country

CHAPTER 6: LEUKEMIA THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL

  • 6.1. Overview
    • 6.1.1. Market size and forecast
  • 6.2. Hospital Pharmacies
    • 6.2.1. Key market trends, growth factors and opportunities
    • 6.2.2. Market size and forecast, by region
    • 6.2.3. Market share analysis by country
  • 6.3. Drug Store and Retail Pharmacies
    • 6.3.1. Key market trends, growth factors and opportunities
    • 6.3.2. Market size and forecast, by region
    • 6.3.3. Market share analysis by country
  • 6.4. Online Providers
    • 6.4.1. Key market trends, growth factors and opportunities
    • 6.4.2. Market size and forecast, by region
    • 6.4.3. Market share analysis by country

CHAPTER 7: LEUKEMIA THERAPEUTICS MARKET, BY REGION

  • 7.1. Overview
    • 7.1.1. Market size and forecast By Region
  • 7.2. North America
    • 7.2.1. Key trends and opportunities
    • 7.2.2. Market size and forecast, by Type
    • 7.2.3. Market size and forecast, by Drug Class
    • 7.2.4. Market size and forecast, by Distribution channel
    • 7.2.5. Market size and forecast, by country
      • 7.2.5.1. U.S.
      • 7.2.5.1.1. Key market trends, growth factors and opportunities
      • 7.2.5.1.2. Market size and forecast, by Type
      • 7.2.5.1.3. Market size and forecast, by Drug Class
      • 7.2.5.1.4. Market size and forecast, by Distribution channel
      • 7.2.5.2. Canada
      • 7.2.5.2.1. Key market trends, growth factors and opportunities
      • 7.2.5.2.2. Market size and forecast, by Type
      • 7.2.5.2.3. Market size and forecast, by Drug Class
      • 7.2.5.2.4. Market size and forecast, by Distribution channel
      • 7.2.5.3. Mexico
      • 7.2.5.3.1. Key market trends, growth factors and opportunities
      • 7.2.5.3.2. Market size and forecast, by Type
      • 7.2.5.3.3. Market size and forecast, by Drug Class
      • 7.2.5.3.4. Market size and forecast, by Distribution channel
  • 7.3. Europe
    • 7.3.1. Key trends and opportunities
    • 7.3.2. Market size and forecast, by Type
    • 7.3.3. Market size and forecast, by Drug Class
    • 7.3.4. Market size and forecast, by Distribution channel
    • 7.3.5. Market size and forecast, by country
      • 7.3.5.1. Germany
      • 7.3.5.1.1. Key market trends, growth factors and opportunities
      • 7.3.5.1.2. Market size and forecast, by Type
      • 7.3.5.1.3. Market size and forecast, by Drug Class
      • 7.3.5.1.4. Market size and forecast, by Distribution channel
      • 7.3.5.2. France
      • 7.3.5.2.1. Key market trends, growth factors and opportunities
      • 7.3.5.2.2. Market size and forecast, by Type
      • 7.3.5.2.3. Market size and forecast, by Drug Class
      • 7.3.5.2.4. Market size and forecast, by Distribution channel
      • 7.3.5.3. UK
      • 7.3.5.3.1. Key market trends, growth factors and opportunities
      • 7.3.5.3.2. Market size and forecast, by Type
      • 7.3.5.3.3. Market size and forecast, by Drug Class
      • 7.3.5.3.4. Market size and forecast, by Distribution channel
      • 7.3.5.4. Italy
      • 7.3.5.4.1. Key market trends, growth factors and opportunities
      • 7.3.5.4.2. Market size and forecast, by Type
      • 7.3.5.4.3. Market size and forecast, by Drug Class
      • 7.3.5.4.4. Market size and forecast, by Distribution channel
      • 7.3.5.5. Spain
      • 7.3.5.5.1. Key market trends, growth factors and opportunities
      • 7.3.5.5.2. Market size and forecast, by Type
      • 7.3.5.5.3. Market size and forecast, by Drug Class
      • 7.3.5.5.4. Market size and forecast, by Distribution channel
      • 7.3.5.6. Rest of Europe
      • 7.3.5.6.1. Key market trends, growth factors and opportunities
      • 7.3.5.6.2. Market size and forecast, by Type
      • 7.3.5.6.3. Market size and forecast, by Drug Class
      • 7.3.5.6.4. Market size and forecast, by Distribution channel
  • 7.4. Asia-Pacific
    • 7.4.1. Key trends and opportunities
    • 7.4.2. Market size and forecast, by Type
    • 7.4.3. Market size and forecast, by Drug Class
    • 7.4.4. Market size and forecast, by Distribution channel
    • 7.4.5. Market size and forecast, by country
      • 7.4.5.1. Japan
      • 7.4.5.1.1. Key market trends, growth factors and opportunities
      • 7.4.5.1.2. Market size and forecast, by Type
      • 7.4.5.1.3. Market size and forecast, by Drug Class
      • 7.4.5.1.4. Market size and forecast, by Distribution channel
      • 7.4.5.2. China
      • 7.4.5.2.1. Key market trends, growth factors and opportunities
      • 7.4.5.2.2. Market size and forecast, by Type
      • 7.4.5.2.3. Market size and forecast, by Drug Class
      • 7.4.5.2.4. Market size and forecast, by Distribution channel
      • 7.4.5.3. India
      • 7.4.5.3.1. Key market trends, growth factors and opportunities
      • 7.4.5.3.2. Market size and forecast, by Type
      • 7.4.5.3.3. Market size and forecast, by Drug Class
      • 7.4.5.3.4. Market size and forecast, by Distribution channel
      • 7.4.5.4. Australia
      • 7.4.5.4.1. Key market trends, growth factors and opportunities
      • 7.4.5.4.2. Market size and forecast, by Type
      • 7.4.5.4.3. Market size and forecast, by Drug Class
      • 7.4.5.4.4. Market size and forecast, by Distribution channel
      • 7.4.5.5. South Korea
      • 7.4.5.5.1. Key market trends, growth factors and opportunities
      • 7.4.5.5.2. Market size and forecast, by Type
      • 7.4.5.5.3. Market size and forecast, by Drug Class
      • 7.4.5.5.4. Market size and forecast, by Distribution channel
      • 7.4.5.6. Rest of Asia-Pacific
      • 7.4.5.6.1. Key market trends, growth factors and opportunities
      • 7.4.5.6.2. Market size and forecast, by Type
      • 7.4.5.6.3. Market size and forecast, by Drug Class
      • 7.4.5.6.4. Market size and forecast, by Distribution channel
  • 7.5. LAMEA
    • 7.5.1. Key trends and opportunities
    • 7.5.2. Market size and forecast, by Type
    • 7.5.3. Market size and forecast, by Drug Class
    • 7.5.4. Market size and forecast, by Distribution channel
    • 7.5.5. Market size and forecast, by country
      • 7.5.5.1. Brazil
      • 7.5.5.1.1. Key market trends, growth factors and opportunities
      • 7.5.5.1.2. Market size and forecast, by Type
      • 7.5.5.1.3. Market size and forecast, by Drug Class
      • 7.5.5.1.4. Market size and forecast, by Distribution channel
      • 7.5.5.2. Saudi Arabia
      • 7.5.5.2.1. Key market trends, growth factors and opportunities
      • 7.5.5.2.2. Market size and forecast, by Type
      • 7.5.5.2.3. Market size and forecast, by Drug Class
      • 7.5.5.2.4. Market size and forecast, by Distribution channel
      • 7.5.5.3. South Africa
      • 7.5.5.3.1. Key market trends, growth factors and opportunities
      • 7.5.5.3.2. Market size and forecast, by Type
      • 7.5.5.3.3. Market size and forecast, by Drug Class
      • 7.5.5.3.4. Market size and forecast, by Distribution channel
      • 7.5.5.4. Rest of LAMEA
      • 7.5.5.4.1. Key market trends, growth factors and opportunities
      • 7.5.5.4.2. Market size and forecast, by Type
      • 7.5.5.4.3. Market size and forecast, by Drug Class
      • 7.5.5.4.4. Market size and forecast, by Distribution channel

CHAPTER 8: COMPETITIVE LANDSCAPE

  • 8.1. Introduction
  • 8.2. Top winning strategies
  • 8.3. Product Mapping of Top 10 Player
  • 8.4. Competitive Dashboard
  • 8.5. Competitive Heatmap
  • 8.6. Top player positioning, 2021

CHAPTER 9: COMPANY PROFILES

  • 9.1. Abbvie Inc
    • 9.1.1. Company overview
    • 9.1.2. Key Executives
    • 9.1.3. Company snapshot
    • 9.1.4. Operating business segments
    • 9.1.5. Product portfolio
    • 9.1.6. Business performance
    • 9.1.7. Key strategic moves and developments
  • 9.2. Amgen Inc.
    • 9.2.1. Company overview
    • 9.2.2. Key Executives
    • 9.2.3. Company snapshot
    • 9.2.4. Operating business segments
    • 9.2.5. Product portfolio
    • 9.2.6. Business performance
    • 9.2.7. Key strategic moves and developments
  • 9.3. Pfizer Inc.
    • 9.3.1. Company overview
    • 9.3.2. Key Executives
    • 9.3.3. Company snapshot
    • 9.3.4. Operating business segments
    • 9.3.5. Product portfolio
    • 9.3.6. Business performance
    • 9.3.7. Key strategic moves and developments
  • 9.4. Novartis AG
    • 9.4.1. Company overview
    • 9.4.2. Key Executives
    • 9.4.3. Company snapshot
    • 9.4.4. Operating business segments
    • 9.4.5. Product portfolio
    • 9.4.6. Business performance
  • 9.5. Gilead Sciences, Inc.
    • 9.5.1. Company overview
    • 9.5.2. Key Executives
    • 9.5.3. Company snapshot
    • 9.5.4. Operating business segments
    • 9.5.5. Product portfolio
    • 9.5.6. Business performance
    • 9.5.7. Key strategic moves and developments
  • 9.6. Bristol-Myers Squibb Company
    • 9.6.1. Company overview
    • 9.6.2. Key Executives
    • 9.6.3. Company snapshot
    • 9.6.4. Operating business segments
    • 9.6.5. Product portfolio
    • 9.6.6. Business performance
    • 9.6.7. Key strategic moves and developments
  • 9.7. Sanofi
    • 9.7.1. Company overview
    • 9.7.2. Key Executives
    • 9.7.3. Company snapshot
    • 9.7.4. Operating business segments
    • 9.7.5. Product portfolio
    • 9.7.6. Business performance
  • 9.8. Teva Pharmaceutical Industries Limited
    • 9.8.1. Company overview
    • 9.8.2. Key Executives
    • 9.8.3. Company snapshot
    • 9.8.4. Operating business segments
    • 9.8.5. Product portfolio
    • 9.8.6. Business performance
  • 9.9. Lupin
    • 9.9.1. Company overview
    • 9.9.2. Key Executives
    • 9.9.3. Company snapshot
    • 9.9.4. Operating business segments
    • 9.9.5. Product portfolio
    • 9.9.6. Business performance
  • 9.10. Takeda Pharmaceutical Company Limited
    • 9.10.1. Company overview
    • 9.10.2. Key Executives
    • 9.10.3. Company snapshot
    • 9.10.4. Operating business segments
    • 9.10.5. Product portfolio
    • 9.10.6. Business performance
    • 9.10.7. Key strategic moves and developments

LIST OF TABLES

  • TABLE 01. GLOBAL LEUKEMIA THERAPEUTICS MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 02. LEUKEMIA THERAPEUTICS MARKET FOR ACUTE LYMPHOCYTIC LEUKEMIA, BY REGION, 2021-2031 ($MILLION)
  • TABLE 03. LEUKEMIA THERAPEUTICS MARKET FOR ACUTE MYELOID LEUKEMIA, BY REGION, 2021-2031 ($MILLION)
  • TABLE 04. LEUKEMIA THERAPEUTICS MARKET FOR CHRONIC LYMPHOCYTIC LEUKEMIA, BY REGION, 2021-2031 ($MILLION)
  • TABLE 05. LEUKEMIA THERAPEUTICS MARKET FOR CHRONIC MYELOID LEUKEMIA, BY REGION, 2021-2031 ($MILLION)
  • TABLE 06. LEUKEMIA THERAPEUTICS MARKET FOR OTHERS, BY REGION, 2021-2031 ($MILLION)
  • TABLE 07. GLOBAL LEUKEMIA THERAPEUTICS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
  • TABLE 08. LEUKEMIA THERAPEUTICS MARKET FOR CHEMOTHERAPY, BY REGION, 2021-2031 ($MILLION)
  • TABLE 09. LEUKEMIA THERAPEUTICS MARKET FOR TARGETED THERAPY AND IMMUNOTHERAPY, BY REGION, 2021-2031 ($MILLION)
  • TABLE 10. GLOBAL LEUKEMIA THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 11. LEUKEMIA THERAPEUTICS MARKET FOR HOSPITAL PHARMACIES, BY REGION, 2021-2031 ($MILLION)
  • TABLE 12. LEUKEMIA THERAPEUTICS MARKET FOR DRUG STORE AND RETAIL PHARMACIES, BY REGION, 2021-2031 ($MILLION)
  • TABLE 13. LEUKEMIA THERAPEUTICS MARKET FOR ONLINE PROVIDERS, BY REGION, 2021-2031 ($MILLION)
  • TABLE 14. LEUKEMIA THERAPEUTICS MARKET, BY REGION, 2021-2031 ($MILLION)
  • TABLE 15. NORTH AMERICA LEUKEMIA THERAPEUTICS MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 16. NORTH AMERICA LEUKEMIA THERAPEUTICS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
  • TABLE 17. NORTH AMERICA LEUKEMIA THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 18. NORTH AMERICA LEUKEMIA THERAPEUTICS MARKET, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 19. U.S. LEUKEMIA THERAPEUTICS MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 20. U.S. LEUKEMIA THERAPEUTICS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
  • TABLE 21. U.S. LEUKEMIA THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 22. CANADA LEUKEMIA THERAPEUTICS MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 23. CANADA LEUKEMIA THERAPEUTICS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
  • TABLE 24. CANADA LEUKEMIA THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 25. MEXICO LEUKEMIA THERAPEUTICS MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 26. MEXICO LEUKEMIA THERAPEUTICS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
  • TABLE 27. MEXICO LEUKEMIA THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 28. EUROPE LEUKEMIA THERAPEUTICS MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 29. EUROPE LEUKEMIA THERAPEUTICS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
  • TABLE 30. EUROPE LEUKEMIA THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 31. EUROPE LEUKEMIA THERAPEUTICS MARKET, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 32. GERMANY LEUKEMIA THERAPEUTICS MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 33. GERMANY LEUKEMIA THERAPEUTICS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
  • TABLE 34. GERMANY LEUKEMIA THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 35. FRANCE LEUKEMIA THERAPEUTICS MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 36. FRANCE LEUKEMIA THERAPEUTICS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
  • TABLE 37. FRANCE LEUKEMIA THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 38. UK LEUKEMIA THERAPEUTICS MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 39. UK LEUKEMIA THERAPEUTICS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
  • TABLE 40. UK LEUKEMIA THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 41. ITALY LEUKEMIA THERAPEUTICS MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 42. ITALY LEUKEMIA THERAPEUTICS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
  • TABLE 43. ITALY LEUKEMIA THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 44. SPAIN LEUKEMIA THERAPEUTICS MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 45. SPAIN LEUKEMIA THERAPEUTICS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
  • TABLE 46. SPAIN LEUKEMIA THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 47. REST OF EUROPE LEUKEMIA THERAPEUTICS MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 48. REST OF EUROPE LEUKEMIA THERAPEUTICS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
  • TABLE 49. REST OF EUROPE LEUKEMIA THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 50. ASIA-PACIFIC LEUKEMIA THERAPEUTICS MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 51. ASIA-PACIFIC LEUKEMIA THERAPEUTICS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
  • TABLE 52. ASIA-PACIFIC LEUKEMIA THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 53. ASIA-PACIFIC LEUKEMIA THERAPEUTICS MARKET, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 54. JAPAN LEUKEMIA THERAPEUTICS MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 55. JAPAN LEUKEMIA THERAPEUTICS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
  • TABLE 56. JAPAN LEUKEMIA THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 57. CHINA LEUKEMIA THERAPEUTICS MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 58. CHINA LEUKEMIA THERAPEUTICS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
  • TABLE 59. CHINA LEUKEMIA THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 60. INDIA LEUKEMIA THERAPEUTICS MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 61. INDIA LEUKEMIA THERAPEUTICS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
  • TABLE 62. INDIA LEUKEMIA THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 63. AUSTRALIA LEUKEMIA THERAPEUTICS MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 64. AUSTRALIA LEUKEMIA THERAPEUTICS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
  • TABLE 65. AUSTRALIA LEUKEMIA THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 66. SOUTH KOREA LEUKEMIA THERAPEUTICS MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 67. SOUTH KOREA LEUKEMIA THERAPEUTICS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
  • TABLE 68. SOUTH KOREA LEUKEMIA THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 69. REST OF ASIA-PACIFIC LEUKEMIA THERAPEUTICS MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 70. REST OF ASIA-PACIFIC LEUKEMIA THERAPEUTICS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
  • TABLE 71. REST OF ASIA-PACIFIC LEUKEMIA THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 72. LAMEA LEUKEMIA THERAPEUTICS MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 73. LAMEA LEUKEMIA THERAPEUTICS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
  • TABLE 74. LAMEA LEUKEMIA THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 75. LAMEA LEUKEMIA THERAPEUTICS MARKET, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 76. BRAZIL LEUKEMIA THERAPEUTICS MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 77. BRAZIL LEUKEMIA THERAPEUTICS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
  • TABLE 78. BRAZIL LEUKEMIA THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 79. SAUDI ARABIA LEUKEMIA THERAPEUTICS MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 80. SAUDI ARABIA LEUKEMIA THERAPEUTICS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
  • TABLE 81. SAUDI ARABIA LEUKEMIA THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 82. SOUTH AFRICA LEUKEMIA THERAPEUTICS MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 83. SOUTH AFRICA LEUKEMIA THERAPEUTICS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
  • TABLE 84. SOUTH AFRICA LEUKEMIA THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 85. REST OF LAMEA LEUKEMIA THERAPEUTICS MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 86. REST OF LAMEA LEUKEMIA THERAPEUTICS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
  • TABLE 87. REST OF LAMEA LEUKEMIA THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 88. ABBVIE INC: KEY EXECUTIVES
  • TABLE 89. ABBVIE INC: COMPANY SNAPSHOT
  • TABLE 90. ABBVIE INC: PRODUCT SEGMENTS
  • TABLE 91. ABBVIE INC: PRODUCT PORTFOLIO
  • TABLE 92. ABBVIE INC: KEY STRATERGIES
  • TABLE 93. AMGEN INC.: KEY EXECUTIVES
  • TABLE 94. AMGEN INC.: COMPANY SNAPSHOT
  • TABLE 95. AMGEN INC.: PRODUCT SEGMENTS
  • TABLE 96. AMGEN INC.: PRODUCT PORTFOLIO
  • TABLE 97. AMGEN INC.: KEY STRATERGIES
  • TABLE 98. PFIZER INC.: KEY EXECUTIVES
  • TABLE 99. PFIZER INC.: COMPANY SNAPSHOT
  • TABLE 100. PFIZER INC.: PRODUCT SEGMENTS
  • TABLE 101. PFIZER INC.: PRODUCT PORTFOLIO
  • TABLE 102. PFIZER INC.: KEY STRATERGIES
  • TABLE 103. NOVARTIS AG: KEY EXECUTIVES
  • TABLE 104. NOVARTIS AG: COMPANY SNAPSHOT
  • TABLE 105. NOVARTIS AG: PRODUCT SEGMENTS
  • TABLE 106. NOVARTIS AG: PRODUCT PORTFOLIO
  • TABLE 107. GILEAD SCIENCES, INC.: KEY EXECUTIVES
  • TABLE 108. GILEAD SCIENCES, INC.: COMPANY SNAPSHOT
  • TABLE 109. GILEAD SCIENCES, INC.: PRODUCT SEGMENTS
  • TABLE 110. GILEAD SCIENCES, INC.: PRODUCT PORTFOLIO
  • TABLE 111. GILEAD SCIENCES, INC.: KEY STRATERGIES
  • TABLE 112. BRISTOL-MYERS SQUIBB COMPANY: KEY EXECUTIVES
  • TABLE 113. BRISTOL-MYERS SQUIBB COMPANY: COMPANY SNAPSHOT
  • TABLE 114. BRISTOL-MYERS SQUIBB COMPANY: PRODUCT SEGMENTS
  • TABLE 115. BRISTOL-MYERS SQUIBB COMPANY: PRODUCT PORTFOLIO
  • TABLE 116. BRISTOL-MYERS SQUIBB COMPANY: KEY STRATERGIES
  • TABLE 117. SANOFI: KEY EXECUTIVES
  • TABLE 118. SANOFI: COMPANY SNAPSHOT
  • TABLE 119. SANOFI: PRODUCT SEGMENTS
  • TABLE 120. SANOFI: PRODUCT PORTFOLIO
  • TABLE 121. TEVA PHARMACEUTICAL INDUSTRIES LIMITED: KEY EXECUTIVES
  • TABLE 122. TEVA PHARMACEUTICAL INDUSTRIES LIMITED: COMPANY SNAPSHOT
  • TABLE 123. TEVA PHARMACEUTICAL INDUSTRIES LIMITED: PRODUCT SEGMENTS
  • TABLE 124. TEVA PHARMACEUTICAL INDUSTRIES LIMITED: PRODUCT PORTFOLIO
  • TABLE 125. LUPIN: KEY EXECUTIVES
  • TABLE 126. LUPIN: COMPANY SNAPSHOT
  • TABLE 127. LUPIN: PRODUCT SEGMENTS
  • TABLE 128. LUPIN: PRODUCT PORTFOLIO
  • TABLE 129. TAKEDA PHARMACEUTICAL COMPANY LIMITED: KEY EXECUTIVES
  • TABLE 130. TAKEDA PHARMACEUTICAL COMPANY LIMITED: COMPANY SNAPSHOT
  • TABLE 131. TAKEDA PHARMACEUTICAL COMPANY LIMITED: PRODUCT SEGMENTS
  • TABLE 132. TAKEDA PHARMACEUTICAL COMPANY LIMITED: PRODUCT PORTFOLIO
  • TABLE 133. TAKEDA PHARMACEUTICAL COMPANY LIMITED: KEY STRATERGIES

LIST OF FIGURES

  • FIGURE 01. LEUKEMIA THERAPEUTICS MARKET, 2021-2031
  • FIGURE 02. SEGMENTATION OF LEUKEMIA THERAPEUTICS MARKET, 2021-2031
  • FIGURE 03. TOP INVESTMENT POCKETS IN LEUKEMIA THERAPEUTICS MARKET (2022-2031)
  • FIGURE 04. MODERATE BARGAINING POWER OF SUPPLIERS
  • FIGURE 05. MODERATE BARGAINING POWER OF BUYERS
  • FIGURE 06. MODERATE THREAT OF SUBSTITUTES
  • FIGURE 07. HIGH THREAT OF NEW ENTRANTS
  • FIGURE 08. MODERATE INTENSITY OF RIVALRY
  • FIGURE 09. DRIVERS, RESTRAINTS AND OPPORTUNITIES: GLOBALLEUKEMIA THERAPEUTICS MARKET
  • FIGURE 10. LEUKEMIA THERAPEUTICS MARKET, BY TYPE, 2021(%)
  • FIGURE 11. COMPARATIVE SHARE ANALYSIS OF LEUKEMIA THERAPEUTICS MARKET FOR ACUTE LYMPHOCYTIC LEUKEMIA, BY COUNTRY 2021-2031(%)
  • FIGURE 12. COMPARATIVE SHARE ANALYSIS OF LEUKEMIA THERAPEUTICS MARKET FOR ACUTE MYELOID LEUKEMIA, BY COUNTRY 2021-2031(%)
  • FIGURE 13. COMPARATIVE SHARE ANALYSIS OF LEUKEMIA THERAPEUTICS MARKET FOR CHRONIC LYMPHOCYTIC LEUKEMIA, BY COUNTRY 2021-2031(%)
  • FIGURE 14. COMPARATIVE SHARE ANALYSIS OF LEUKEMIA THERAPEUTICS MARKET FOR CHRONIC MYELOID LEUKEMIA, BY COUNTRY 2021-2031(%)
  • FIGURE 15. COMPARATIVE SHARE ANALYSIS OF LEUKEMIA THERAPEUTICS MARKET FOR OTHERS, BY COUNTRY 2021-2031(%)
  • FIGURE 16. LEUKEMIA THERAPEUTICS MARKET, BY DRUG CLASS, 2021(%)
  • FIGURE 17. COMPARATIVE SHARE ANALYSIS OF LEUKEMIA THERAPEUTICS MARKET FOR CHEMOTHERAPY, BY COUNTRY 2021-2031(%)
  • FIGURE 18. COMPARATIVE SHARE ANALYSIS OF LEUKEMIA THERAPEUTICS MARKET FOR TARGETED THERAPY AND IMMUNOTHERAPY, BY COUNTRY 2021-2031(%)
  • FIGURE 19. LEUKEMIA THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2021(%)
  • FIGURE 20. COMPARATIVE SHARE ANALYSIS OF LEUKEMIA THERAPEUTICS MARKET FOR HOSPITAL PHARMACIES, BY COUNTRY 2021-2031(%)
  • FIGURE 21. COMPARATIVE SHARE ANALYSIS OF LEUKEMIA THERAPEUTICS MARKET FOR DRUG STORE AND RETAIL PHARMACIES, BY COUNTRY 2021-2031(%)
  • FIGURE 22. COMPARATIVE SHARE ANALYSIS OF LEUKEMIA THERAPEUTICS MARKET FOR ONLINE PROVIDERS, BY COUNTRY 2021-2031(%)
  • FIGURE 23. LEUKEMIA THERAPEUTICS MARKET BY REGION, 2021
  • FIGURE 24. U.S. LEUKEMIA THERAPEUTICS MARKET, 2021-2031 ($MILLION)
  • FIGURE 25. CANADA LEUKEMIA THERAPEUTICS MARKET, 2021-2031 ($MILLION)
  • FIGURE 26. MEXICO LEUKEMIA THERAPEUTICS MARKET, 2021-2031 ($MILLION)
  • FIGURE 27. GERMANY LEUKEMIA THERAPEUTICS MARKET, 2021-2031 ($MILLION)
  • FIGURE 28. FRANCE LEUKEMIA THERAPEUTICS MARKET, 2021-2031 ($MILLION)
  • FIGURE 29. UK LEUKEMIA THERAPEUTICS MARKET, 2021-2031 ($MILLION)
  • FIGURE 30. ITALY LEUKEMIA THERAPEUTICS MARKET, 2021-2031 ($MILLION)
  • FIGURE 31. SPAIN LEUKEMIA THERAPEUTICS MARKET, 2021-2031 ($MILLION)
  • FIGURE 32. REST OF EUROPE LEUKEMIA THERAPEUTICS MARKET, 2021-2031 ($MILLION)
  • FIGURE 33. JAPAN LEUKEMIA THERAPEUTICS MARKET, 2021-2031 ($MILLION)
  • FIGURE 34. CHINA LEUKEMIA THERAPEUTICS MARKET, 2021-2031 ($MILLION)
  • FIGURE 35. INDIA LEUKEMIA THERAPEUTICS MARKET, 2021-2031 ($MILLION)
  • FIGURE 36. AUSTRALIA LEUKEMIA THERAPEUTICS MARKET, 2021-2031 ($MILLION)
  • FIGURE 37. SOUTH KOREA LEUKEMIA THERAPEUTICS MARKET, 2021-2031 ($MILLION)
  • FIGURE 38. REST OF ASIA-PACIFIC LEUKEMIA THERAPEUTICS MARKET, 2021-2031 ($MILLION)
  • FIGURE 39. BRAZIL LEUKEMIA THERAPEUTICS MARKET, 2021-2031 ($MILLION)
  • FIGURE 40. SAUDI ARABIA LEUKEMIA THERAPEUTICS MARKET, 2021-2031 ($MILLION)
  • FIGURE 41. SOUTH AFRICA LEUKEMIA THERAPEUTICS MARKET, 2021-2031 ($MILLION)
  • FIGURE 42. REST OF LAMEA LEUKEMIA THERAPEUTICS MARKET, 2021-2031 ($MILLION)
  • FIGURE 43. TOP WINNING STRATEGIES, BY YEAR
  • FIGURE 44. TOP WINNING STRATEGIES, BY DEVELOPMENT
  • FIGURE 45. TOP WINNING STRATEGIES, BY COMPANY
  • FIGURE 46. PRODUCT MAPPING OF TOP 10 PLAYERS
  • FIGURE 47. COMPETITIVE DASHBOARD
  • FIGURE 48. COMPETITIVE HEATMAP: LEUKEMIA THERAPEUTICS MARKET
  • FIGURE 49. TOP PLAYER POSITIONING, 2021
  • FIGURE 50. ABBVIE INC: NET REVENUE, 2019-2021 ($MILLION)
  • FIGURE 51. ABBVIE INC: REVENUE SHARE BY SEGMENT, 2021 (%)
  • FIGURE 52. ABBVIE INC: REVENUE SHARE BY REGION, 2021 (%)
  • FIGURE 53. AMGEN INC.: NET REVENUE, 2019-2021 ($MILLION)
  • FIGURE 54. AMGEN INC.: REVENUE SHARE BY REGION, 2021 (%)
  • FIGURE 55. PFIZER INC.: NET REVENUE, 2019-2021 ($MILLION)
  • FIGURE 56. PFIZER INC.: REVENUE SHARE BY SEGMENT, 2021 (%)
  • FIGURE 57. PFIZER INC.: REVENUE SHARE BY REGION, 2021 (%)
  • FIGURE 58. NOVARTIS AG: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 59. NOVARTIS AG: REVENUE SHARE BY SEGMENT, 2022 (%)
  • FIGURE 60. NOVARTIS AG: REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 61. GILEAD SCIENCES, INC.: NET REVENUE, 2019-2021 ($MILLION)
  • FIGURE 62. BRISTOL-MYERS SQUIBB COMPANY: NET SALES, 2019-2021 ($MILLION)
  • FIGURE 63. BRISTOL-MYERS SQUIBB COMPANY: REVENUE SHARE BY REGION, 2021 (%)
  • FIGURE 64. SANOFI: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 65. SANOFI: REVENUE SHARE BY SEGMENT, 2021 (%)
  • FIGURE 66. SANOFI: REVENUE SHARE BY REGION, 2021 (%)
  • FIGURE 67. TEVA PHARMACEUTICAL INDUSTRIES LIMITED: NET REVENUE, 2019-2021 ($MILLION)
  • FIGURE 68. TEVA PHARMACEUTICAL INDUSTRIES LIMITED: REVENUE SHARE BY SEGMENT, 2021 (%)
  • FIGURE 69. LUPIN: NET SALES, 2019-2021 ($MILLION)
  • FIGURE 70. LUPIN: REVENUE SHARE BY REGION, 2021 (%)
  • FIGURE 71. TAKEDA PHARMACEUTICAL COMPANY LIMITED: NET REVENUE, 2019-2021 ($MILLION)
  • FIGURE 72. TAKEDA PHARMACEUTICAL COMPANY LIMITED: REVENUE SHARE BY REGION, 2021 (%)